Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma.
10.6065/apem.2015.20.3.150
- Author:
Ju Hyun AHN
1
;
Wan Hyeong CHO
;
Jun Ah LEE
;
Dong Ho KIM
;
Ju Hee SEO
;
Jung Sub LIM
Author Information
1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea. limjs@kcch.re.kr
- Publication Type:Original Article
- Keywords:
Osteosarcoma;
Osteoporosis;
Bone density;
Korea
- MeSH:
Absorptiometry, Photon;
Adolescent;
Bone Density*;
Chemotherapy, Adjuvant*;
Child;
Drug Therapy;
Femur;
Femur Neck;
Humans;
Korea;
Metabolism;
Osteoporosis;
Osteosarcoma*;
Retrospective Studies;
Spine;
Survivors
- From:Annals of Pediatric Endocrinology & Metabolism
2015;20(3):150-154
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Osteoporosis is currently receiving particular attention as a sequela in survivors of childhood osteosarcoma. The aim of this study was to evaluate bone mineral density (BMD) changes during methotrexate-based chemotherapy in children and adolescents with osteosarcoma. METHODS: Nine patients with osteosarcoma were included in this retrospective study and compared with eight healthy controls. BMD of the lumbar spine and unaffected femur neck of patients was serially measured by dual-energy x-ray absorptiometry (DXA) before and just after chemotherapy and compared with controls. RESULTS: Four patients (44%) showed decreased lumbar spine BMD and seven patients (78%) showed decreased femur neck BMD, while all controls showed increased lumbar and femur BMD (P=0.024 and P=0.023). The femur neck BMD z-scores decreased from -0.49+/-1.14 to -1.63+/-1.50 (P=0.032). At the end of therapy, five patients (56%) showed femur neck BMD z-scores below -2.0. CONCLUSION: The bone metabolism is disturbed during therapy in children with osteosarcoma, resulting in a reduced BMD with respect to healthy controls. Since a reduced BMD predisposes to osteoporosis, specific attention and therapeutic interventions should be considered.
